JP7691488B2 - 肺疾患を治療するための方法及び組成物 - Google Patents

肺疾患を治療するための方法及び組成物 Download PDF

Info

Publication number
JP7691488B2
JP7691488B2 JP2023503444A JP2023503444A JP7691488B2 JP 7691488 B2 JP7691488 B2 JP 7691488B2 JP 2023503444 A JP2023503444 A JP 2023503444A JP 2023503444 A JP2023503444 A JP 2023503444A JP 7691488 B2 JP7691488 B2 JP 7691488B2
Authority
JP
Japan
Prior art keywords
msc
exo
pharmaceutical composition
mscs
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023503444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534524A5 (https=
JP2023534524A (ja
Inventor
レボビッツ、カイム
アリチャ、リヴァイタル
レヴィ、ヨセフ
カーン、ラルフ
カスピ、ハガイ
セモ、ジョナサン
Original Assignee
ブレインストーム セル セラペウティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブレインストーム セル セラペウティクス リミテッド filed Critical ブレインストーム セル セラペウティクス リミテッド
Publication of JP2023534524A publication Critical patent/JP2023534524A/ja
Publication of JP2023534524A5 publication Critical patent/JP2023534524A5/ja
Priority to JP2025089972A priority Critical patent/JP2025128209A/ja
Application granted granted Critical
Publication of JP7691488B2 publication Critical patent/JP7691488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023503444A 2020-07-20 2021-07-20 肺疾患を治療するための方法及び組成物 Active JP7691488B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025089972A JP2025128209A (ja) 2020-07-20 2025-05-29 肺疾患を治療するための方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053780P 2020-07-20 2020-07-20
US63/053,780 2020-07-20
US202163133350P 2021-01-03 2021-01-03
US63/133,350 2021-01-03
PCT/IL2021/050885 WO2022018729A1 (en) 2020-07-20 2021-07-20 Methods and compositions for treating lung conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025089972A Division JP2025128209A (ja) 2020-07-20 2025-05-29 肺疾患を治療するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2023534524A JP2023534524A (ja) 2023-08-09
JP2023534524A5 JP2023534524A5 (https=) 2025-01-24
JP7691488B2 true JP7691488B2 (ja) 2025-06-11

Family

ID=77265158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023503444A Active JP7691488B2 (ja) 2020-07-20 2021-07-20 肺疾患を治療するための方法及び組成物
JP2025089972A Pending JP2025128209A (ja) 2020-07-20 2025-05-29 肺疾患を治療するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025089972A Pending JP2025128209A (ja) 2020-07-20 2025-05-29 肺疾患を治療するための方法及び組成物

Country Status (7)

Country Link
US (1) US20230310507A1 (https=)
EP (1) EP4181935A1 (https=)
JP (2) JP7691488B2 (https=)
AU (1) AU2021313472B2 (https=)
CA (1) CA3189818A1 (https=)
IL (1) IL299997A (https=)
WO (1) WO2022018729A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
WO2022114730A2 (ko) * 2020-11-26 2022-06-02 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 감염성 질환 치료용 조성물
KR20240003167A (ko) * 2022-06-30 2024-01-08 주식회사 지씨셀 편도유래줄기세포를 유효성분으로 포함하는 감염성 폐 질환의 예방 또는 치료용 조성물
WO2024236603A1 (en) * 2023-05-18 2024-11-21 Khorakiwala Zahabiya Growth factor concentrate composition
CN116897887A (zh) * 2023-07-31 2023-10-20 湖南中医药大学 一种病毒性哮喘动物模型的构建方法
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522212A (ja) 2007-03-22 2010-07-01 オシリス セラピューティクス，インコーポレイティド 間充織幹細胞とその使用
JP2014507482A (ja) 2011-03-11 2014-03-27 チルドレンズ メディカル センター コーポレーション 間葉系幹細胞エキソソームに関連する方法および組成物
JP2015531594A (ja) 2012-08-06 2015-11-05 ブレインストーム セル セラペウティクス リミテッド 神経栄養因子を分泌する間葉系幹細胞の作製方法
JP2019511509A (ja) 2016-04-15 2019-04-25 サムソン ライフ パブリック ウェルフェア ファウンデーション トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物
WO2019198077A1 (en) 2018-04-10 2019-10-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN111212653A (zh) * 2017-08-15 2020-05-29 儿童医学中心公司 经纯化间充质干细胞外排体及其用途
GB2568255A (en) * 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics
EP4344739A3 (en) * 2018-06-29 2024-05-29 North Carolina State University Therapeutic lung repair by inhalation of lung spheroid cell-secreted factors
CA3170255A1 (en) * 2020-03-05 2021-09-10 Silviu Itescu Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230105667A1 (en) * 2020-03-12 2023-04-06 Exostem Biotec Ltd. Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis
BR112022020042A2 (pt) * 2020-04-03 2022-11-22 Mesoblast Int Sarl Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
EP4132479A1 (en) * 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522212A (ja) 2007-03-22 2010-07-01 オシリス セラピューティクス，インコーポレイティド 間充織幹細胞とその使用
JP2014507482A (ja) 2011-03-11 2014-03-27 チルドレンズ メディカル センター コーポレーション 間葉系幹細胞エキソソームに関連する方法および組成物
JP2015531594A (ja) 2012-08-06 2015-11-05 ブレインストーム セル セラペウティクス リミテッド 神経栄養因子を分泌する間葉系幹細胞の作製方法
JP2019511509A (ja) 2016-04-15 2019-04-25 サムソン ライフ パブリック ウェルフェア ファウンデーション トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物
WO2019198077A1 (en) 2018-04-10 2019-10-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof
JP2021520790A (ja) 2018-04-10 2021-08-26 ブレインストーム セル セラペウティクス リミテッド 細胞型特異的エキソソームおよびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Turkish Journal of Biology，2020年05月04日，Vol.44，pp.273-282

Also Published As

Publication number Publication date
EP4181935A1 (en) 2023-05-24
IL299997A (en) 2023-03-01
AU2021313472B2 (en) 2025-10-16
AU2021313472A1 (en) 2023-02-23
CA3189818A1 (en) 2022-01-27
JP2023534524A (ja) 2023-08-09
US20230310507A1 (en) 2023-10-05
WO2022018729A1 (en) 2022-01-27
JP2025128209A (ja) 2025-09-02

Similar Documents

Publication Publication Date Title
JP7691488B2 (ja) 肺疾患を治療するための方法及び組成物
WO2021180237A1 (zh) 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
JP6773563B2 (ja) エキソソームに関連する方法および組成物
JP6105846B2 (ja) 虚血組織の細胞療法
US10723997B2 (en) Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell
CN115212230B (zh) 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
CN112826833A (zh) 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
KR102464099B1 (ko) 다능성 간세포에 의한 허혈재관류 폐장애의 경감 및 치료
Xu et al. Safety, efficacy and bio-distribution analysis of exosomes derived from human umbilical cord mesenchymal stem cells for effective treatment of bronchopulmonary dysplasia by intranasal administration in mice model
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
Abreu et al. Serum from patients with asthma potentiates macrophage phagocytosis and human mesenchymal stromal cell therapy in experimental allergic asthma
WO2025082103A1 (zh) Cd146+间充质干细胞在制备预防和/或治疗脑卒中的药物中的用途
CN116897887A (zh) 一种病毒性哮喘动物模型的构建方法
US20230241116A1 (en) Treatment of complications caused by infections of severe acute respiratory syndrome coronavirus
CA3177704A1 (en) Stem cells for treatment of respiratory disorders
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса
Hassen et al. Studying the therapeutic effect of umbilical cord stem cell in pneumonia caused by covid-19
Yildirim An Interventional Study on the Late Treatment of Severe Bronchopulmonary Dysplasia in Preterm Infants Using Mesenchymal Stromal Cells
US20240000850A1 (en) Methods and compositions for allergy and asthma treatment using fibroblasts
HK40082197A (en) Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof
HK40089111A (zh) 结合蛋白质的细胞外囊泡的制造方法
CN121731215A (zh) 一种基于间充质干细胞来源外泌体的促睡眠鼻喷剂及其制备和应用
Fu et al. Transfusion with human umbilical cord mesenchymal stem cells improves liver function in hepatitis B patients with decompensated liver cirrhosis
WO2007089102A1 (en) Composition for treating developmental and/or chronic lung diseases comprising cells separated or proliferated from umbilical cord blood
Moawed et al. Assessment of cord blood vascular endothelial growth factor levels and circulating CD34+ cells in preterm infants with respiratory distress syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250530

R150 Certificate of patent or registration of utility model

Ref document number: 7691488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150